Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li>Metropolis Healthcare's initial public offering opens on April 3 and closes on April 5.</li><li>The company is a leading diagnostics chain with presence in 197 cities in 19 states.</li><li>HDFC Securities has lined up a set of key risks that may affect investor returns.</li></ul> Metropolis Healthcare is a leading diagnostics chain in India with presence in 197 cities in 19 states across the country. What works in its favour is the headroom for growth in the sector and the locations in which the company is active. The country's diagnostics industry is expected to grow at a compounded rate of 16% in three years starting April 2018 and be worth $12.3 billion by March 2020, according to investment advisors in HDFC Securities said in a report. There are very few Pan-India chains, which together have a share of approximately 35 to 40% of the organized diagnostic market. Regional chains constitute the rest of the market, the report added. 
 
 
 
 
 
 
 <div type="javascript" title="Custom" contenttype="Image"><cdata><![CDATA[
<div class="flourish-embed" data-src="visualisation/276106"></div>
]]></cdata></div>















 While the dearth of branded chains offers an opportunity, regional peers and standalone centres also pose a pricing challenge for companies like Metropolis. 
 <div type="javascript" title="Custom" contenttype="Image"><cdata><![CDATA[
<div class="flourish-embed" data-src="visualisation/276879"></div>
]]></cdata></div>



 Aside from the competition and other business risks-- renewal of licences and approvals, technological advancements, potential government pricing controls, reliance on third party services-- there are other risks pointed out by analysts. Potential legal threats There are several outstanding legal proceedings against Metropolis, subsidiaries, directors and promoters. In particular, the company has sought to compound certain offences under the Companies Act, 2013 before the NCLT and the Registrar of Companies. Further, it has been issued a summon cum show cause notice from the Assistant Provident Fund Commissioner, Employees’ Provident Fund Organisation, Ministry of Labour and Employment, and the government of India. It cannot be assured that these outstanding legal proceedings will be decided in Company’s favor or in favor of its Subsidiaries, Directors or Promoters, or that no further liability will arise out of these proceedings. Further, such legal proceedings could divert management’s time and attention and consume financial resources. A sour joint venture Metropolis Healthcare owns a 34% stake in Star Metropolis, a joint venture in the United Arab Emirates with ETA Star Healthcare. However, the two companies have had certain disagreements since 2011 and Star Metropolis stopped providing any information, including financial information. Further, one of the affiliates of the partner in UAE has been using the ‘Metropolis’ brand to market its pathology services in the Gulf Cooperation Council. This may adversely affect the Indian company and its brand. The trademark is yet to be registered The company has applied for a trademark registration of its logo and name 'Metropolis' and is yet to be approved. There are other risks to intellectual property too. "Infringement claims could also arise in the future as patents could be issued on tests or processes that MHL may be performing, particularly in such emerging areas as gene-based testing and other specialty testing. Any of the foregoing could have an adverse effect on its business, results of operations and financial condition," the report said. The brand is key ingredient to the potential success of the company. Pledged stake Nearly 30% of the stake held by the promoters of the company are to pledged with lenders after the share sale. Promoters may pledge more shares in accordance with terms of the loan after the shares are listed. "Any default under the agreements pursuant to which these Equity Shares would be pledged will entitle the pledgee to enforce the pledge over these Equity Shares," according to the report. A promoter group company is also obliged to inform and take consent of some lenders before carrying out certain activities and entering into certain transactions.

A new IPO in India has its eyes on a $12.3 billion market-- but there are many risks

<ul><li><keyword id="12496770" type="General" weightage="20" keywordseo="tarsons-products-ipo" source="Orion">Tarsons Products IPO</keyword> is all set to list in stock exchanges tomorrow, November 26.</li><li>Investors have shown good interest in the IPO as it has been subscribed 77.49 times.</li><li>The grey market premium of the Indian labware company has come down to ₹170 from ₹200 earlier.</li></ul>Indian labware company Tarsons Products is all set to list its initial public offering (IPO) on stock exchanges tomorrow, November 26. The IPO has shown a good response from investors as it has been subscribed 77.49 times. While the company was looking to raise ₹1,024 crore through the IPO, it received bids for ₹55,625 crore. Investors have bid for 84 crore stocks out of 1.08 stock available for bids. <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Investors </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscription status </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Qualified Institutional Investors </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">115.77 times </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Non-Institutional Investors </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">184.58 times </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Retail </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">10.56 times </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Overall </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">77.49 times </td></tr></tbody></table> However, the grey market premium of the Indian labware company has come down to ₹170 from ₹200 earlier. The IPO consisted of a fresh issue of equity shares worth ₹150 crore and an offer for sale (OFS) of 1.32 crore equity shares that will be sold by promoters and an investor. Some of the company’s clients include Dr Reddy's Laboratories, Metropolis Healthcare, Dr. Lal Path Labs. Tarsons sells nearly one in every ten labware products sold in India. Analysts are betting big on the healthcare sector even post covid and expect the labware products company to continue growing. “COVID has turned out to be a boon for the companies in the healthcare space as worldwide governments have started allocating more funds and people in general have become more conscious towards the healthcare benefits. We expect the firm to grow faster than current CAGR [compound annual growth rate] given the laboratory instrument industry is growing at 20%,” said analysts at Nirmal Bang. Tarsons Products is engaged in designing, developing, manufacturing and supplying a diverse range of quality labware products used in laboratories across research organisations, academic institutes, pharmaceutical firms, diagnostics companies and hospitals. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/how-to-check-go-fashions-ipo-allotment-status/articleshow/87891055.cms">Go Fashion IPO’s allotment status would be announced today, GMP at ₹425</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/reliance-industries-coal-india-and-other-top-stocks-to-watch-out-for-on-november-25/slidelist/87901109.cms">Reliance Industries, Coal India and other top stocks to watch out for on November 25</a>

Tarsons Products IPO listing tomorrow; GMP staggers around ₹170

<ul><li>Tarsons Products’ ₹1,000 crore IPO had opened on November 15 and will close on November 17.</li><li>Nearly one in every ten lab equipment sold in India is from Tarsons.</li><li>The <keyword id="938640" type="General" weightage="20" keywordseo="grey-market-premium" source="Orion">grey market premium</keyword> of the Indian labware company surged to ₹230 from ₹200.</li><li>Check out the latest news and updates on Business Insider.</li></ul>Today is the second day to subscribe to the Indian labware company Tarsons Products initial public offering (IPO), which will close on November 17. Some of the company’s clients include Dr Reddy's Laboratories, Metropolis Healthcare, Dr. Lal Path Labs. Tarsons sells nearly one in every ten labware products sold in India. The ₹1,024 crore IPO consists of a fresh issue of equity shares worth ₹150 crore and an offer for sale (OFS) of 1.32 crore equity shares that will be sold by promoters and an investor. The company said it will repay debt with the money from the IPO and build its sixth manufacturing facility at Panchla in West Bengal . Tarsons Products is engaged in designing, developing, manufacturing and supplying a diverse range of quality labware products used in laboratories across research organisations, academic institutes, pharmaceutical firms, diagnostics companies and hospitals. <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Broking firms </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Recommendation </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Ventura Securities </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Nirmal Bang </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Angel One </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Investmentz </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe for long term </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Swastika </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Ashika Research </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe for long term </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Choice Broking </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe with caution </td></tr></tbody></table> Analysts are betting big on the healthcare sector even post covid and expect the labware products company to continue growing. The grey market premium of the Indian labware company surged to ₹230 from ₹200 earlier. “Covid has turned out to be a boon for the companies in the healthcare space as worldwide governments have started allocating more funds and people in general have become more conscious towards the healthcare benefits. We expect the firm to grow faster than current CAGR given the laboratory instrument industry is growing at 20%,” said analysts at Nirmal Bang. <div type="image" title="tarsons product" height="900" width="1200" msid="87730870" hostid="261"></div> Besides, the fact that the company cut down its debt by half in two years has impressed analysts. The company total borrowings came down to ₹33 crore in FY21 from ₹64 crore in FY19. Further, the company said it will utilise ₹78 crore from the IPO proceeds to repay/prepayment debt. “The margins of the company have grown significantly on the back of declining debt. The company aims to be debt free post the IPO and is planning for CAPEX (capital expenditure) which will further increase the revenues,” said analysts at Swastika. However, analysts at Choice Broking believe that the sharp spike in growth last year may be a one-off event triggered by the pandemic and the company may find it difficult to maintain the same pace in the future. “There is a respectable import market for the company to capture and also a huge export opportunity arising from the “China plus one” strategy, in case the globe adopts this strategy in the post-Covid period. Thus considering the future growth outlook and the demanded premium valuation, we assign a “Subscribe with Caution” rating for the issue,” the report said. Simply put, the threat of international competition and rising imports is just as valid as the hope of a boom in business for Tarsons. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/policybazzar-and-sigachi-share-price-jump-in-early-trading/articleshow/87730171.cms">Policybazaar gets a boost after an American fund laps up 3.4 million shares and Sigachi hits upper circuit on the morning after listing</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/personal-finance/news/now-you-can-invest-in-global-blockchain-companies-through-this-mutual-fund-heres-how-to-do-it/articleshow/87724967.cms">Now you can invest in global blockchain companies through this mutual fund ⁠— here's how to do it</a>

The IPO from Tarsons, a Bengal-based supplier for Dr Lal Path Labs and Dr Reddy’s, gets a unanimous ‘subscribe’ call from the street

<ul><li>Shares of Tarsons Products listed at ₹700 while the price band was fixed at ₹635-662 per share.</li><li>The IPO was a hit among investors as it has been subscribed just 77.49 times on the last day of the bidding.</li><li>The market capitalisation of the company stood at ₹3,724 crore.</li></ul>Shares of Indian labware company Tarsons Products made a decent listing on the National Stock Exchange (NSE) and BSE despite weak market trends. The stock listed at ₹700, higher 5.74% on the issue price band of ₹635-662 apiece. Investors were expecting a positive listing despite weak market trends as the fundamentals of the company like becoming debt-free, having strong cash flow looked attractive. “The company has a strong cash flow and it is likely to become debt-free post-IPO [initial public offering] however the valuations look expensive therefore aggressive investors with a long-term view can hold this stock while those who were playing for listing gain should book profit because we are expecting some listing gain of around 20-25% based on subscription figure and grey market trend current GMP 180 (+27%),” said Aayush Agrawal, senior research analyst, merchant banking at Swastika Investmart. Post listing, the market capitalisation of the company stood at ₹3,724 crore, according to BSE data. The shares of Tarsons Products were trading at ₹722, higher by 9% at 10.00 a.m., on November 26. The grey market had indicated a strong listing too as unlisted shares of Tarsons Products were commanding a marginal premium of ₹180 per share. The IPO, which was open between November 15 and November 17, received strong response from investors. It was subscribed 77.49 times on the last day of the bidding. Tarsons Products is engaged in designing, developing, manufacturing and supplying a diverse range of quality labware products used in laboratories across research organisations, academic institutes, pharmaceutical firms, diagnostics companies and hospitals. Some of the company’s clients include Dr Reddy's Laboratories, Metropolis Healthcare, Dr. Lal Path Labs. Tarsons sells nearly one in every ten labware products sold in India. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/startups/news/ratan-tata-backed-upstox-is-now-valued-more-than-its-rivals-zerodha-and-groww/articleshow/87922976.cms">Ratan Tata-backed Upstox is now valued more than its rivals Zerodha and Groww</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/reliance-industries-tarsons-products-asian-paints-and-other-hot-stocks-on-november-26/slidelist/87921730.cms">Reliance Industries, Tarsons Products, Asian Paints and other hot stocks on November 26</a>

Tarsons Products makes a decent stock market debut amid weak market trend; lists at 6% premium

From Nykaa to Cipla to 3i infotech — these are some of the themes the market is betting on amid a sell-off

Metropolis <keyword id="6354525" type="COMPANY" weightage="60" keywordseo="Healthcare">Healthcare</keyword> is one among the top 3 diagnostic chains in the country. It claims to deliver over 15 million tests a year and to serve over 10,000 Laboratories, Hospitals, Nursing homes and 2,00,000 Consultants. 
 
It’s also the country’s only multinational chain of diagnostic centres with presence in UAE, Sri Lanka, South Africa, Kenya, Mauritius and Ghana. It processes over 4500 varieties of tests and employs over 3500 people. 
 Business Insider sat down with current Managing Director and CEO <keyword id="584350" type="UNKNOWN" weightage="80" keywordseo="Ameera-Shah">Ameera Shah</keyword>, to discuss the Indian <a href="http://www.businessinsider.in/searchresult.cms?query=healthcare+space&amp;sortorder=effectivedate">healthcare space</a> and the future of upcoming <a href="http://www.businessinsider.in/searchresult.cms?query=healthcare+startups&amp;sortorder=effectivedate">healthcare startups</a>. 
 
How’s India similar to other SE Asian markets you’re in? 
All these markets have something in common – <a href="http://www.businessinsider.in/searchresult.cms?query=health+insurance&amp;sortorder=effectivedate">health insurance</a> hasn’t penetrated here in a big way, so people are paying out of their pockets. 
 
That changes the dynamics of the market. Doctors are more careful before prescribing tests, and patients are more careful of the pricing. Here patients become the decision-maker. That’s why convenience is of supreme importance. 
 
We’re seeing double digit growth rate (10-13%) in emerging markets as compared to developed markets in Europe and America which see single digit growth. 
 
Is affordability still the key factor in emerging markets? 
Quality is the number one parameter, affordability comes next. The third one is convenience, and the fourth emerging factor is consumer experience. As education levels rise, people expect a level of hospitality. 
 
Market Size for Diagnostics in India. 
The market is currently $ 5-6 billion, and the top 3 players have managed to get only 10% of the total market. Over time we’ll see that changing. 
 
In the US, 40% of the market is held by the top 3 players, and that’s because of <a href="http://www.businessinsider.in/searchresult.cms?query=health+insurance&amp;sortorder=effectivedate">health insurance</a> penetration. 
 
How do you strike a balance between the latest tech and still make it affordable? 
In the western world people talk about how technology can help reduce cost. In India, manual labor is cheaper. 
 
When it comes to the latest tech, we don’t compromise. However, if something doesn’t affect the quality of the report we choose manual. 
 
Do you see <keyword id="3172082" type="UNKNOWN" weightage="60" keywordseo="healthcare-startups">healthcare startups</keyword> being sucked into the mainstream anytime soon? 
Startups are happening in two main areas – medical devices and mainly IT, with aggregators and the likes. 
 
In medical devices there still hasn’t been a startup that has revolutionized laboratory methods. In the IT space, it’s primarily in the <a href="http://www.businessinsider.in/searchresult.cms?query=preventive+healthcare&amp;sortorder=effectivedate">preventive space</a>. That’s not working in a large way because in healthcare people go with a brand they trust, and they don’t want a new brand that’s coming out of nowhere. There’s some traction because of deep discounting, but how they’ll sustain in the long term is anybody’s guess. 
 
So aggregators may not claim a big part of your business anytime soon? 
Not at all. 
 
The assumption is that once <a href="http://www.businessinsider.in/searchresult.cms?query=Practo&amp;sortorder=effectivedate">Practo</a> and the likes make inroads into doctors’ clinics, they can tell the doctor where to send the patient for diagnostics. However, these are <a href="http://www.businessinsider.in/searchresult.cms?query=IT+software&amp;sortorder=effectivedate">IT software</a> companies, but the Doctor will send a patient to a hospital based on his medical knowledge. 
 
What happens with services like these is that patients search for doctors like a directory of services. However, there’s no quality listing. 
 
Patients still go by word of mouth versus a recommendation by an IT app. 
 
Unless the quality listing comes into play, its difficult, and that raises a 2nd question – how will they determine what is a good doctor from a bad one. Doctors/Diagnostic chains can’t be rated by stars or quantifiable parameters. 
 
How they’ll make these lists is a little bit of a question mark. 
 
What kind of a startup can help you take a leap into the next stage of your expansion? 
At this point, I don’t see a model. Rather, we can help startups. 
 
They are absolutely new in healthcare, and they don’t have either the track record, or the brand value that doctors trust. There is an asymmetry in consumer education in India. 
 
More work on consumer education might be helpful for brands like us. 
 
Do you see the word-of-mouth recommendation model changing anytime soon for healthcare? 
There are no alternatives. 
 
You rather believe a distant niece, nephew or cousin who’s been to the clinic rather than a random website where you don’t know how they’ve done the listing. You’re going to believe a website basis what! 
 
People don’t want to take chances with their health. That’s the biggest barrier for any new player, and also what protects the industry. 
 
Any plans for an IPO? 
I don’t see anything in the next 6 months. 
 
Our industry is seeing great valuations in the public market, and as a company which has built a presence, it’s a very good opportunity for us if we do decide to go public.

You Searched For "Metropolis Healthcare IPO" and got 7 results

A new IPO in India has its eyes on a $12.3 billion market-- but there are many risks

Sriram Iyer

Tarsons Products IPO listing tomorrow; GMP staggers around ₹170

Bhakti Makwana

The IPO from Tarsons, a Bengal-based supplier for Dr Lal Path Labs and Dr Reddy’s, gets a unanimous ‘subscribe’ call from the street

Bhakti Makwana

Tarsons Products makes a decent stock market debut amid weak market trend; lists at 6% premium

Bhakti Makwana

From Nykaa to Cipla to 3i infotech — these are some of the themes the market is betting on amid a sell-off

Bhakti Makwana

Exclusive: ‘You’re going to believe a website basis what!’ : In conversation with Metropolis MD-CEO Ameera Shah

Saikat Pyne

A rare interview with Salesforce cofounder Parker Harris

Eugene Kim

Popular Keywords

Buying Guides